Amgen

News

Viridian takes aim at Amgen's Tepezza with veligrotug data

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian

News

US immunology biotech Zenas BioPharma files $100m IPO

Just a few months after raising $200 million in third-round financing, immunology specialist Zenas BioPharma has filed an initial public offering in the US seeking to add another $100 milli

News

$refractory chronic gout$

Sobi starts rolling FDA filing for chronic gout drug

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu

Oncology

Paul Burton interview with Jonah Comstock

ASCO 2024 - Paul Burton

For Amgen, ASCO 2024 was all about lung cancer, with encouraging data in both non-small cell and small cell lung cancer.

News

Amgen preps Uplizna filing for a second indication

Amgen has moved closer to a second indication for its B cell-depleting therapy Uplizna, acquired as part of its $27.8 billion takeover of Horizon Therapeutics last year, a

News

FDA clears Amgen’s Bkemv as first biosimilar of Soliris

The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemi

Viridian takes aim at Amgen's Tepezza with veligrotug data

US immunology biotech Zenas BioPharma files $100m IPO

Sobi starts rolling FDA filing for chronic gout drug

ASCO 2024 - Paul Burton

Amgen preps Uplizna filing for a second indication

FDA clears Amgen’s Bkemv as first biosimilar of Soliris

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Amgen

Editor's Picks